Document:

Exhibit 10.3

 

 

 

Warrant
Agreement

 

Dated
as of February 14, 2022

 

 

 

    	 

     

    

 

WARRANT
AGREEMENT (this “Agreement”), dated as of February 14, 2022, by AgeX Therapeutics, Inc., a Delaware corporation (the “Company”),
for the benefit of Juvenescence Limited which, along with any permitted successor Holder of a Warrant, is referred to herein as a “Lender”.

 

Section
1. Issuance of Warrants.

 

1.1 Number
of Warrants. Pursuant to the Loan Agreement, the Company has agreed to issue to Lender Warrants to purchase a number of shares of
Company Common Stock upon each Advance (as defined in the Loan Agreement) determined in accordance with Section 3.4 of the Loan Agreement
(such shares, the “Warrant Shares”), subject to adjustment as provided herein. The certificates representing the Warrants
shall be issued to the Lender upon the funding of each advance shall be issued to the Lender in accordance with Section 3.5 of the Loan
Agreement.

 

1.2 Expiration
Date. The right to exercise the Warrants shall expire on, and the Warrants may not be exercised after, 5:00 p.m. New York time on
the third anniversary of the issuance thereof.

 

1.3 Form
of Warrant. The text of the Warrants and of the Exercise Notice shall be substantially as set forth in Exhibit A attached hereto.

 

1.4 Signatures;
Date of Warrants. The Warrants shall be executed on behalf of the Company by its Chief Executive Officer and attested by its Chief
Financial Officer or Secretary or any Assistant Secretary (or persons performing similar functions) on the date of issuance. The signature
of any such officers on the Warrants may be manual or facsimile or other legally permissible electronic format. Warrants bearing the
manual, facsimile or electronic signatures of individuals who were at any time the proper officers of the Company shall bind the Company,
notwithstanding that such individuals or any one of them shall have ceased to hold such offices prior to the delivery of such Warrants
or did not hold such offices on the date of this Agreement. In the event that the Company shall appoint a warrant agent to act on its
behalf in connection with the division, transfer, exchange or exercise of Warrants, the Warrants issued after the date of such appointment
shall be dated as of the date of countersignature thereof by the warrant agent upon division, exchange, substitution or transfer. Until
such time as the Company shall appoint a warrant agent, Warrants shall be dated as of the date of execution thereof by the Company either
upon initial issuance or upon division, exchange, substitution or transfer.

 

1.5 Countersignature
of Warrants. In the event that the Company shall appoint a warrant agent to act on its behalf in connection with the division,
transfer, exchange or exercise of Warrants, the Warrants issued after the date of such appointment shall be countersigned by the
warrant agent (or any successor to the warrant agent then acting as warrant agent) and shall not be valid for any purpose unless so
countersigned. Warrants may be countersigned, however, by the warrant agent (or by its successor as warrant agent hereunder) and may
be delivered by the warrant agent, notwithstanding that the persons whose manual, facsimile or electronic signatures appear thereon
as proper officers of the Company shall have ceased to be such officers at the time of such countersignature, issuance or delivery.
The warrant agent (if so appointed) shall, upon written instructions of the Chief Executive Officer or the Chief Financial Officer
(or persons performing similar functions) of the Company, countersign, issue and deliver the Warrants as provided in this
Agreement.

 

    	1

     

    

 

Section
2. Warrant Price. Subject to any adjustments required by Section 6, the price per share at which Warrant Shares shall be purchasable
upon exercise of a Warrant (the “Warrant Price”) shall be equal to the Market Price determined at the time specified and
in accordance with Section 3.4 of the Loan Agreement.

 

Section
3. Exercise of Warrants; Restrictions.

 

3.1 Exercise
of Warrants. Subject to the terms of this Agreement, for each Warrant issued hereunder, Holder shall have the right, which may be
exercised in whole or in part, to purchase from the Company, at the applicable Warrant Price then in effect, the number of fully paid
and nonassessable Warrant Shares determined as provided in this Agreement. The Warrants may not be exercised or transferred after the
Expiration Date. A Warrant may be exercised by (i) surrender of the certificate evidencing the Warrant to be exercised, together with
the Exercise Notice duly completed and signed, to the Company at its principal office (or if appointed, the principal office of the warrant
agent) and (ii) payment of the applicable Warrant Price to the Company (or if appointed, to the warrant agent for the account of the
Company), for the number of Warrant Shares in respect of which the Warrant is then being exercised. Payment of the aggregate Warrant
Price shall be made by bank wire transfer to the account of the Company or by bank cashier’s check.

 

3.2 Issuance
of Warrant Shares. Subject to Section 3.3 and the Holder’s payment of any taxes or deposit funds with the Company sufficient
to pay any taxes payable by the Holder pursuant to Section 5, following the surrender of any Warrant with the Exercise Notice duly completed
and signed, and provided that payment of the Warrant Price has been received, the Company (or if appointed, the warrant agent) shall
promptly cause to be issued and delivered to or upon the written order of the Holder and in such name or names as the Holder may designate,
a certificate or certificates for the number of full Warrant Shares so purchased upon the exercise of such Warrant, together with cash,
as provided in Section 8, in respect of any fractional Warrant Shares otherwise issuable upon such exercise. Such Warrant Share certificate
or certificates shall be deemed to have been issued and any person so designated to be named therein shall be deemed to have become a
Holder of record of such Warrant Shares as of the date on which the Warrant with the duly completed and signed Exercise Notice and payment
of the Warrant Price, as aforesaid, shall have been received by the Company (or if appointed, to the warrant agent for the account of
the Company), for such Warrant Shares. Except for cash payable in respect of any fractional share, under no circumstances shall the Company
be required to settle any exercises of this Warrant by cash payment or otherwise “net cash settle” this Warrant. In the event
that a certificate evidencing any Warrant is exercised in respect of less than all of the Warrant Shares purchasable on such exercise
at any time prior to the tenth Business Day prior to the Expiration Date, a new certificate evidencing the unexercised portion of the
Warrant will be issued, and the warrant agent (if so appointed) is hereby irrevocably authorized to countersign and to deliver the required
new Warrant certificate or certificates. The Company, whenever required by the warrant agent (if appointed), will supply the warrant
agent with Warrant certificates duly executed on behalf of the Company for such purpose.

 

    	2

     

    

 

 3.3 Restrictions on Exercise of Warrants.

 

(a) The
Warrants may not be exercised unless the issuance of the Warrant Shares thereunder is registered under the Securities Act or an exemption
from such registration is available.

 

(b) Unless
the Warrant and Warrant Shares have been registered under the Securities Act and under any applicable state securities laws, each Person
who is exercising a Warrant and who does not certify in the applicable Exercise Notice that such Person either is an “accredited
investor” as defined in Rule 501 under the Securities Act or is not a “U.S. person” as defined in Rule 902 under the
Securities Act, may be required to provide a written opinion of counsel, acceptable to the Company and to the transfer agent of the Warrant
Shares, to the effect that exercise of the Warrant and the issuance of the Warrant Shares are exempt from registration under the Securities
Act and under any applicable state securities laws.

 

(c) The
Company shall be entitled to obtain, as a condition precedent to its issuance of any certificates representing Warrant Shares or any
other securities issuable upon any exercise of a Warrant, a letter or other instrument from the Holder containing such representations
or warranties by the Holder as reasonably deemed necessary by the Company to effect compliance by the Company with the requirements of
the Securities Act and any other applicable United States federal and/or state securities laws.

 

(d) Any
exercise, attempt to exercise, or purported exercise of a Warrant in violation of the restrictions set forth in this Section 3.3 shall
be deemed null and void and of no binding effect.

 

(e) The
Company will refuse to issue, and will issue instructions to the transfer agent and registrar of its Warrant Shares to refuse to issue,
any Warrant Shares upon any exercise not made pursuant to registration under the Securities Act and applicable state securities laws,
or pursuant to an available exemption from registration under the Securities Act and applicable state securities laws.

 

(f) If
under the rules of the Applicable Exchange, approval by the stockholders of Company would be required in connection with the exercise
of all or any portion of the Warrant Shares, then unless and until such stockholder approval has been obtained, the maximum amount of
Warrant Shares that may be issued upon exercise of the Warrants shall be an amount entitling Lender to receive a number of Warrant Shares
that, when added to (i) any Shares owned by Lender immediately prior to such exercise and (ii) any Shares issued to Lender upon such
exercise of Warrants, would equal the 50% Cap. To the extent any Warrants cannot be exercised because of the 50% Cap at any time (including
after giving effect to the assumed conversion or exercise of any other securities or instruments held by the Lender that are convertible
into or exercisable for Common Stock), such Warrants shall remain outstanding and the Company shall use commercially reasonable efforts
to obtain its stockholders’ approval at the Company’s next annual meeting of stockholders the issuance of Warrant Shares
in excess of the 50% Cap limitation, and the Expiration Date of each Warrant shall be the date sixty (60) days following the date of
such annual meeting or the original Expiration Date, whichever is later.

 

    	3

     

    

 

Section
4. Transferability of Warrants and Warrant Shares; Restrictions on Transfer.

 

4.1 Registration.
Each Warrant shall be numbered and shall be registered on the books of the Company (the “Warrant Register”) as issued. The
Company and the warrant agent (if appointed) shall be entitled to treat the registered holder of any Warrant appearing in the Warrant
Register as the owner in fact of the Warrant for all purposes and shall not be bound to recognize any equitable or other claim or interest
in the Warrant on the part of any other person, and shall not be liable for any registration of transfer of any Warrant which is registered
or to be registered in the name of a fiduciary or the nominee of a fiduciary upon the instruction of such fiduciary, unless made with
the actual knowledge that a fiduciary or nominee is committing a breach of trust in requesting such registration of transfer, or with
such knowledge of such facts that its participation therein amounts to bad faith. Each Warrant shall initially be registered in the name
of the Person to whom it is originally issued.

 

4.2 Transfer.
Subject to Section 4.3, the Warrants shall be transferable only on the Warrant Register upon delivery of the Warrant certificate duly
endorsed by the Holder of the Warrant or by such Holder’s duly authorized attorney or representative, or accompanied by proper
evidence of succession, assignment or authority to transfer. In all cases of transfer by an attorney, the original power of attorney
or a duly certified copy thereof shall be deposited and remain with the Company (or the warrant agent, if appointed). In case of transfer
by executors, administrators, guardians or other legal representatives, duly authenticated evidence of their authority shall be produced,
and may be required to be deposited and remain with the Company (or the warrant agent, if appointed) in its discretion. Upon any registration
of transfer, the Company shall execute and deliver (or if appointed, the warrant agent shall countersign and deliver) a new Warrant or
Warrants to the Persons entitled thereto.

 

 4.3 Restrictions on Transfer of Warrants and Warrant Shares.

 

(a) The
Warrants, and any Warrant Shares issued upon the exercise of the Warrants, may not be sold, pledged, hypothecated, transferred or assigned,
in whole or in part, unless a registration statement under the Securities Act, and under any applicable state securities laws, is effective
therefor, or an exemption from such registration is then available and an opinion of counsel, acceptable to the Company and to the transfer
agent or warrant agent, if any, has been rendered stating that such sale, pledge, hypothecation, transfer or assignment will not violate
the Securities Act or any other United States federal or state securities laws; provided, that no such opinion of counsel shall be required
in the event of a sale to (i) a “qualified institutional buyer” within the meaning of Rule 144A under the Securities Act,
(ii) pursuant to the applicable provisions of Rule 144 under the Securities Act, or (iii) to an “affiliate” of the Holder,
as such term is defined in Rule 405 under the Securities Act.

 

(b) As
a condition precedent to the registration of transfer and issuance of any certificates representing Warrants or Warrant Shares upon transfer,
the Company shall be entitled to obtain a letter or other instrument from the Holder and the proposed transferee containing such representations
or warranties by such Holder and proposed transferee as reasonably deemed necessary by the Company to effect compliance by the Company
with the requirements of the Securities Act and any other applicable federal and/or state securities laws.

 

    	4

     

    

 

(c) Any
sale, pledge, hypothecation, transfer, or assignment of a Warrant or Warrant Shares in violation of the foregoing restrictions shall
be deemed null and void and of no binding effect.

 

(d) The
Company will issue instructions to any warrant agent that may be appointed, and to the transfer agent and registrar of its Warrant Shares,
to refuse to register the transfer of any Warrant and Warrant Shares not made pursuant to registration under the Securities Act and applicable
state securities laws, or pursuant to an available exemption from registration under the Securities Act and applicable state securities
laws.

 

Section
5. Payment of Taxes. The Company will pay all documentary stamp taxes, if any, attributable to the initial issuance of Warrant
Shares upon the exercise of Warrants; provided, however, that the Company shall not be required to pay any tax or taxes which may be
payable in respect of any transfer involved in the issue or delivery of any Warrant or certificates for Warrant Shares in a name other
than that of the Holder of such Warrants or Warrant Shares.

 

Section
6. Adjustment of Warrant Price and Number of Warrant Shares. The number and kind of securities purchasable upon the exercise of
each Warrant and the Warrant Price shall be subject to adjustment from time to time upon the happening of certain events, as provided
in this Section 6.

 

6.1 Adjustments.
If the Company shall (i) pay a dividend in shares of Common Stock or make a distribution in shares of Common Stock, (ii) subdivide its
outstanding shares of Common Stock, (iii) combine its outstanding shares of Common Stock into a smaller number of shares of Common Stock
or (iv) reclassify or change its Common Stock (including any such reclassification or change in connection with a consolidation or merger
in which the Company is the surviving corporation), the number of Warrant Shares purchasable upon exercise of each Warrant immediately
prior thereto shall be adjusted so that the Holder of each Warrant shall be entitled to receive the kind and number of Warrant Shares
or other securities of the Company or other property which the Holder would have owned or have been entitled to receive after the happening
of any of the events described above, had such Warrant been exercised immediately prior to the happening of such event or any record
date with respect thereto. An adjustment made pursuant to this paragraph 6.1 shall become effective immediately after the effective date
of such event retroactive to the record date, if any, for such event.

 

(a) No
adjustment in the number of Warrant Shares purchasable hereunder shall be required unless such adjustment would require an increase or
decrease of at least one percent (1%) in the number of Warrant Shares purchasable upon the exercise of each Warrant; provided, however,
that any adjustments which by reason of this paragraph (a) are not required to be made shall be carried forward and taken into account
in the determination of any subsequent adjustment. All calculations shall be made with respect to the number of Warrant Shares purchasable
hereunder, to the nearest tenth of a share and with respect to the Warrant Price payable hereunder, to the nearest whole cent.

 

    	5

     

    

 

(b) Whenever
the number of Warrant Shares purchasable upon the exercise of each Warrant is adjusted, as herein provided, the Warrant Price payable
upon exercise of each Warrant shall be adjusted by multiplying such Warrant Price immediately prior to such adjustment by a fraction,
of which the numerator shall be the number of Warrant Shares purchasable upon the exercise of each Warrant immediately prior to such
adjustment, and of which the denominator shall be the number of Warrant Shares purchasable immediately thereafter.

 

6.2 Notice
of Adjustment. Whenever the number of Warrant Shares purchasable upon the exercise of each Warrant or the Warrant Price of such Warrant
Shares is adjusted, as herein provided, the Company shall, or in the event that a warrant agent is appointed, the Company shall cause
the warrant agent to, promptly and in any event within ten (10) days send to each Holder notice of such adjustment or adjustments. Such
notice shall set forth the number of Warrant Shares purchasable upon the exercise of each Warrant and the Warrant Price after such adjustment,
setting forth a brief statement of the facts requiring such adjustment and setting forth the computation by which such adjustment was
made.

 

6.3 No
Adjustment for Dividends. Except as set forth in Section 6.1, no adjustment in respect of any dividends shall be made during the
term of a Warrant or upon the exercise of a Warrant.

 

6.4 Preservation
of Purchase Rights Upon Merger, Consolidation, etc. In case of any consolidation of the Company with or merger of the Company or
its subsidiary into another corporation or in case of any sale, assignment, license, lease or other transfer to, or other transaction
or business combination with, another Person for all or substantially all the assets or securities of the Company or its subsidiaries,
or any other transaction constituting, resulting in, or giving effect to a Change of Control (any such transaction or series of related
transactions, a “Sale Transaction”), the Company or such successor, purchasing corporation or other acquiror or transferee,
as the case may be, shall execute an agreement that each Holder shall have the right thereafter, upon such Holder’s election, either
(i) upon payment of the Warrant Price in effect immediately prior to such action, to purchase upon exercise of each Warrant the kind
and amount of shares and other securities and property (including cash) which the Holder would have owned or have been entitled to receive
after the happening of such Sale Transaction had such Warrant been exercised immediately prior to such transaction (such shares and other
securities and property (including cash) being referred to as the “Sale Consideration”) or (ii) to receive, in cancellation
of such Warrant (and in lieu of paying the Warrant Price and exercising such Warrant), the Sale Consideration less a portion thereof
having a fair market value (as reasonably determined by the Company) equal to the Warrant Price (it being understood that, if the Sale
Consideration consists of more than one type of shares, other securities or property, the amount of each type of shares, other securities
or property to be received shall be reduced proportionately), in each case, without regard to any limitations or restrictions on the
exercise thereof; provided, however, that except as set forth in Section 6.1, no adjustment in respect of dividends, interest or other
income on or from such shares or other securities and property shall be made during the term of a Warrant or upon the exercise of a Warrant.
The Company shall promptly e-mail, and mail by first class mail, postage prepaid, to each Holder, notice of the execution of any such
agreement. Such agreement shall provide for adjustments, which shall be as nearly equivalent as may be practicable to the adjustments
provided for in this Section 6. The provisions of this paragraph shall similarly apply to successive Sale Transactions (including subsequent
related transactions). The warrant agent (if appointed) shall be under no duty or responsibility to determine the correctness of any
provisions contained in any such agreement relating to the kind or amount of shares of stock or other securities or property receivable
upon exercise of Warrants or with respect to the method employed and provided therein for any adjustments and shall be entitled to rely
upon the provisions contained in any such agreement.

 

    	6

     

    

 

Section
7. Reservation of Warrant Shares; Purchase and Cancellation of Warrants.

 

7.1 Reservation
of Warrant Shares. There have been reserved, and the Company shall at all times keep reserved, out of its authorized Common Stock,
a number of shares of Common Stock sufficient to provide for the exercise of the rights of purchase represented by the outstanding Warrants.
The Company will keep a copy of this Agreement on file with the transfer agent for the Warrant Shares. The warrant agent, if appointed,
will be irrevocably authorized to requisition from time to time from such transfer agent the stock certificates required to honor outstanding
Warrants upon exercise in accordance with the terms of this Agreement. The Company will supply such transfer agent with duly executed
stock certificates for such purposes and will provide or otherwise make available any cash which may be payable as provided in Section
8. The Company will furnish such transfer agent a copy of all notices of adjustments and certificates related thereto, transmitted to
each Holder pursuant to Section 6.2.

 

7.2 Purchase
of Warrants by the Company. The Company shall have the right, except as limited by law or by other agreements, with the consent of
the Holder (such consent to be given or withheld in the Holder’s sole discretion), to purchase or otherwise acquire Warrants from
the Holder at such times, in such manner and for such consideration as it and the Holder may deem appropriate.

 

7.3 Cancellation
of Warrants. In the event the Company shall purchase or otherwise acquire Warrants, the same shall thereupon be cancelled and retired.
The warrant agent (if so appointed) shall cancel any Warrant surrendered for exchange, substitution, transfer or exercise in whole or
in part.

 

Section
8. Fractional Interests. The Company shall not be required to issue fractional Warrants upon the transfer of any Warrant, or fractional
Warrant Shares upon the exercise of Warrants. If more than one Warrant shall be presented for exercise at the same time by the same Holder,
the number of full Warrant Shares which shall be issuable upon the exercise thereof shall be computed on the basis of the aggregate number
of Warrant Shares purchasable on exercise of the Warrants so presented. If any fraction of a Warrant Share would, except for the provisions
of this Section 8, be issuable on the exercise of any Warrant (or specified portion thereof), the Company shall pay an amount in cash
equal to the Market Price per Warrant Share determined as of one business day prior to the date the Warrant is presented for exercise,
multiplied by such fraction.

 

    	7

     

    

 

Section
9. Exchange of Warrant Certificates. Each Warrant certificate may be exchanged, at the option of the Holder thereof, for another
Warrant certificate or Warrant certificates in different denominations (but not for any fractional Warrant or any denomination that would,
but for Section 8, result in the issuance of a fractional share upon exercise) entitling the Holder or Holders thereof to purchase a
like aggregate number of Warrant Shares as the certificate or certificates surrendered then entitle the Holder to purchase. Any Holder
desiring to exchange a Warrant certificate or certificates shall make such request in writing delivered to the Company at its principal
office (or, if a warrant agent is appointed, the warrant agent at its principal office) and shall surrender, properly endorsed, the certificate
or certificates to be so exchanged. Thereupon, the Company (or, if appointed, the warrant agent) shall execute and deliver to the person
entitled thereto a new Warrant certificate or certificates, as the case may be, as so requested, in such name or names as such Holder
shall designate.

 

Section
10. Mutilated or Missing Warrants. In case any of the certificates evidencing the Warrants shall be mutilated, lost, stolen or
destroyed, the Company may in its discretion issue and deliver (and, if appointed, the warrant agent shall countersign and deliver) in
exchange and substitution for and upon cancellation of the mutilated Warrant certificate, or in lieu of and substitution for the Warrant
certificate lost, stolen or destroyed, a new Warrant certificate of like tenor, but only upon receipt of evidence reasonably satisfactory
to the Company and the warrant agent (if so appointed) of such loss, theft or destruction of such Warrant, and an indemnity or bond,
if requested, also reasonably satisfactory to them. An applicant for such a substitute Warrant certificate shall also comply with such
other reasonable requirements and pay such reasonable charges as the Company (or the warrant agent, if so appointed) may prescribe.

 

Section
11. No Rights as Stockholders; Notices to Holders. Nothing contained in this Agreement or in any of the Warrants shall be
construed as conferring upon the Holders or their transferees the right to vote or to receive dividends or to consent or to receive
notice as stockholders in respect of any meeting of stockholders for the election of directors of the Company or any other matter,
or any rights whatsoever as stockholders of the Company. If, however, at any time prior to the Expiration Date, any of the following
events shall occur: (a) the Company shall declare any dividend payable in any securities upon its shares of Common Stock or make any
distribution (other than a regular cash dividend, as such dividend may be increased from time to time, or a dividend payable in
shares of Common Stock for which an adjustment to the number of Warrant Shares is to be made pursuant to Section 6.1) to the holders
of its shares of Common Stock; (b) the Company shall distribute rights, options or warrants to all holders of its outstanding Common
Stock, without any charge to such holders, entitling them to subscribe for or purchase shares of Common Stock or the Company shall
otherwise offer to the holders of its shares of Common Stock on a pro rata basis any cash, additional shares of Common Stock or
other securities of the Company or any right to subscribe for or purchase any thereof; (c) a Sale Transaction; (d) a dissolution,
liquidation or winding up of the Company; or (e) a transaction between the Company and any other Person that will result in a Change
of Control or other Sale Transaction shall be proposed, then in any one or more of said events the Company shall give notice in
writing of such event as provided in Section 12, such giving of notice to be completed at least 10 days prior to the date fixed as a
record date or the date of closing the transfer books for the determination of the stockholders entitled to such dividend or
distribution or for the determination of stockholders entitled to vote on such proposed merger, consolidation, sale of assets,
dissolution, liquidation or winding up or the date on which a transaction to which the Company is a party and which will cause or
result in a Change of Control or other Sale Transaction will be consummated. Such notice shall specify such record date or the date
of closing the transfer books, as the case may be. Failure to publish, mail or receive such notice or any defect therein or in the
publication or mailing thereof shall not affect the validity of any action in connection with such dividend, distribution or
subscription rights, or such proposed dissolution, liquidation or winding up.

 

    	8

     

    

 

Section
12. Notices; Principal Office. [Any notice pursuant to this Agreement by the Company or by any Holder to the warrant agent (if
so appointed), or by the warrant agent (if so appointed) or by any Holder to the Company, shall be in writing and shall be delivered
in person, or mailed first class, postage prepaid, or sent by air delivery service (a) to the Company, at its office, Attention: Chief
Financial Officer, or (b) to the warrant agent, at its offices as designated at the time the warrant agent is appointed. The address
of the principal office of the Company is 1101 Marina Village Parkway, Alameda, CA 94501. Any notice given pursuant to this Agreement
by the Company or the warrant agent to the Holder shall be in writing and shall be mailed first class, postage prepaid, or sent by air
delivery service, or delivered personally to such Holder at the Holder’s address on the books of the Company or the warrant agent,
as the case may be. A notice shall be deemed given on the date deposited in the United States mail, first class postage prepaid, or on
date deposited with an air delivery service, or on the date delivered if personally delivered. The Company, the warrant agent (if appointed),
and any Holder may from time to time change the address to which notices to it are to be delivered or mailed hereunder by notice given
as provided in this Section 12.

 

Section
13. Successors. Except as expressly provided herein to the contrary, all the covenants and provisions of this Agreement by or
for the benefit of the Company, the warrant agent (if appointed) and the Holder shall bind and inure to the benefit of their respective
successors and permitted assigns hereunder.

 

Section
14. Legends. The Warrants shall bear an appropriate legend, conspicuously disclosing the restrictions on exercise under
Section 3.3, and the Warrants and Warrant Shares shall bear an appropriate legend, conspicuously disclosing the restrictions on
transfer under Section 4.3 until the same are registered for sale under the Securities Act or are transferred in a transaction
exempt from registration under the Securities Act entitling the transferee to receive securities that are not deemed to be
“restricted securities” as such term is defined in Rule 144 under the Securities Act. The Company agrees that upon the
sale of the Warrants and Warrant Shares pursuant to a registration statement or an exemption entitling the transferee to receive
securities that are not deemed to be “restricted securities,” or at such time as registration under the Securities Act
shall no longer be required, upon the presentation of the certificates containing such a legend to the transfer agent or warrant
agent, if any, it will remove such legend; provided, that unless the request for removal of the legend is in connection with a sale
registered under the Securities Act or a sale meeting the applicable requirements of Rule 144 under the Securities Act, the Holder
shall have provided an opinion of counsel, acceptable to the Company and the transfer agent or warrant agent, as applicable, to the
effect that such legend may be removed in compliance with the Securities Act.

 

    	9

     

    

 

Section
15. Applicable Law; Specific Performance. This Agreement and each Warrant issued hereunder shall be governed by and construed
in accordance with the laws of the State of Delaware, without giving effect to principles of conflict of laws. The parties agree that
failure of any party to perform its agreements and covenants hereunder, including a party’s failure to take all actions as are
necessary on such party’s part in accordance with the terms and conditions of any Warrant to consummate the transactions contemplated
hereby, will cause irreparable injury to the other party, for which monetary damages, even if available, will not be an adequate remedy.
It is agreed that the parties shall be entitled to equitable relief including injunctive relief and specific performance of the terms
hereof, without the requirement of posting a bond or other security, and each party hereby consents to the issuance of injunctive relief
by any court of competent jurisdiction to compel performance of a party’s obligations and to the granting by any court of the remedy
of specific performance of such party’s obligations hereunder, this being in addition to any other remedies to which the parties
are entitled at law or equity.

 

Section
16. Benefits of this Agreement. This Agreement shall be for the sole and exclusive benefit of the Company, the warrant agent (if
appointed), and the Holders. Nothing in this Agreement shall be construed to give to any Person other than the Company, the warrant agent
(if appointed), and the Holders any legal or equitable right, remedy or claim under this Agreement.

 

Section
17. Amendments. No amendment, modification or other change to, or waiver of any provision of, this Warrant Agreement or any Warrant
may be made unless such amendment, modification or waiver is set forth in writing and is signed by the Company and the Holder (and, if
appointed, the warrant agent).

 

Section
18. Counterparts. This Agreement may be executed in any number of counterparts (including by separate counterpart signature pages)
and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute
but one and the same instrument.

 

Section
19. Captions. The captions of the Sections and subsections of this Agreement have been inserted for convenience only and shall
have no substantive effect.

 

Section
20. Certain Definitions. For purposes of this Warrant Agreement and the Warrants, the following terms shall have the following
meanings:

 

20.1 “50%
Cap” means one share less than 50% of the total outstanding shares of Company as of the date on which the 50% Cap is determined.

 

20.2 “Applicable
Exchange” means NYSE American stock exchange or any other national stock exchange on which the Warrant Shares are listed.

 

    	10

     

    

 

20.3 “Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or
required by law to remain closed.

 

20.4 “Change
of Control” means (a) a merger or consolidation of the Company with another Person other than (i) a merger in which the Company
is the surviving Person and the holders of Common Stock immediately before the merger hold more than 50% of the Common Stock immediately
after the merger or consolidation, or (ii) a merger solely for the purpose of changing the state of the Company’s incorporation,
(b) a tender offer or similar transaction through which any Person (other than the Holder) or group acquires more than 50% of the outstanding
Common Stock, or (c) a sale of all or substantially all of the assets of the Company and its subsidiaries.

 

20.5 “Common
Stock” means the common stock, par value $0.0001 per share, of the Company and any other capital stock of the Company issued in
exchange therefor or into which such common stock may be converted through any reclassification or recapitalization of such common stock
of the Company; but excluding shares of any other Person into which Company common stock may be converted or exchanged in connection
with a merger or consolidation other than a merger or consolidation solely for the purpose of changing the state of the Company’s
incorporation.

 

 20.6 “Company” means AgeX Therapeutics, Inc., a Delaware corporation.

 

20.7 “Exercise
Notice” shall mean the form of exercise notice on the reverse of the Warrant.

 

 20.8 “Expiration Date” shall have the meaning set forth in Section 1.2.

 

20.9 “Holder”
means a registered holder of a Warrant as reflected on the Warrant Register.

 

20.10 “Loan
Agreement” means that certain Secured Convertible Promissory Note, dated as of the date hereof between and among Juvenescence Limited,
as Lender thereunder, the Company, as Borrower, and certain subsidiaries of the Company named therein, as Guarantors.

 

 20.11 “Market Price” shall have the meaning given to such term in the Loan Agreement.

 

20.12 “Person”
means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization,
any other entity and a government or any department or agency thereof.

 

 20.13 “Sale Consideration” shall have the meaning ascribed in Section 6.4.

 

 20.14 “Sale Transaction” shall have the meaning ascribed in Section 6.4.

 

 20.15 “Securities Act” means the Securities Act of 1933, as amended.

 

20.16 “Warrants”
mean the Common Stock purchase warrants issuable and governed pursuant to this Agreement.

 

 20.17 “Warrant Register” shall have the meaning ascribed in Section 4.1.

 

 20.18 “Warrant Share” shall have the meaning ascribed in Section 1.1.

 

[signature
page follows]

 

    	11

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be duly executed, all as of the day and year first above written.

 

	AGEX THERAPEUTICS, INC.	 
	 	 
	By:	/s/ Michael D. West	 
	Name:	Michael D. West	 
	Title:	Chief Executive Officer	 
	 	 
	Attest:	 
	 	 
	By:	/s/ Andrea Park	 
	Name:	Andrea Park	 
	Title:	Chief Financial Officer	 
	 	 
	JUVENESCENCE LIMITED	 
	 	 
	By:	/s/ Jim Mellon	 
	Name:	Jim Mellon	 
	Title:	Director and Chairman	 

 

    	12

     

    

 

EXHIBIT
A

 

THIS
WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER APPLICABLE
STATE SECURITIES LAWS. THIS WARRANT MAY NOT BE EXERCISED, SOLD, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED EXCEPT PURSUANT TO AN
EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM REGISTRATION. HEDGING TRANSACTIONS INVOLVING THIS WARRANT OR ANY COMMON STOCK OR OTHER SECURITIES ISSUABLE UPON EXERCISE OF THIS
WARRANT MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

VOID
AFTER 5:00 P.M. NEW YORK TIME ON THE EXPIRATION DATE

 

	Certificate
    No.        	Warrant to Purchase
	 	 
	Issue Date: [            ]	[Insert number of Shares]
	 	 
	 	Shares of Common Stock

 

AGEX
THERAPEUTICS, INC.

COMMON STOCK PURCHASE WARRANTS

 

This
certifies that, for value received, or its registered assigns (the “Holder”), is entitled to purchase from AgeX
Therapeutics, Inc., a Delaware corporation (the “Company”), at a purchase price per share of
[                ] Dollars and
[                ] cents
($[          ]) (the “Warrant Price”),
[                (                )]
shares of its Common Stock, par value $0.0001 per share (the “Common Stock”). The number of shares purchasable upon
exercise of the Common Stock Purchase Warrants (the “Warrants”) and the Warrant Price are subject to adjustment from
time to time as set forth in the Warrant Agreement referred to below. Outstanding Warrants not exercised prior to 5:00 p.m., New
York time, on the third anniversary of the original issue date hereof (the “Expiration Date”) shall thereafter be
void.

 

Subject
to restriction specified in the Warrant Agreement, Warrants may be exercised in whole or in part on or after the date hereof by
presentation of this Warrant Certificate with the Exercise Notice on the reverse side hereof duly executed, and simultaneous payment
of the Warrant Price (or as otherwise set forth in Section 6.4 of the Warrant Agreement) at the principal office of the Company (or
if a warrant agent is appointed, at the principal office of the warrant agent). Payment of the Warrant Price shall be made by bank
wire transfer to the account of the Company or by bank cashier’s check as provided in Section 3.1 of the Warrant Agreement. As
provided in the Warrant Agreement, the Warrant Price and the number or kind of shares which may be purchased upon the exercise of
the Warrant evidenced by this Warrant Certificate are, upon the happening of certain events, subject to modification and
adjustment.

 

    	1

    	 

    

 

This
Warrant Certificate is issued under and in accordance with a Warrant Agreement dated as of February [__], 2022 (the “Warrant Agreement”),
and is subject to the terms and provisions contained in the Warrant Agreement, to all of which the Holder of this Warrant Certificate
by acceptance of this Warrant Certificate consents. A copy of the Warrant Agreement may be obtained by the Holder hereof upon written
request to the Company.

 

Upon
any partial exercise of the Warrant evidenced by this Warrant Certificate, there shall be issued to the Holder hereof a new Warrant Certificate
in respect of the shares of Common Stock as to which the Warrant evidenced by this Warrant Certificate shall not have been exercised
to the extent provided in the Warrant Agreement. This Warrant Certificate may be exchanged at the office of the Company (or the warrant
agent, if appointed) by surrender of this Warrant Certificate properly endorsed either separately or in combination with one or more
other Warrant Certificates for one or more new Warrant Certificates evidencing the right of the Holder thereof to purchase the aggregate
number of shares as were purchasable on exercise of the Warrants evidenced by the Warrant Certificate or Certificates exchanged. No fractional
shares will be issued upon the exercise of any Warrant, but the Company will pay the cash value thereof determined as provided in the
Warrant Agreement. This Warrant Certificate is transferable at the office of the Company (or the warrant agent, if appointed) in the
manner and subject to the limitations set forth in the Warrant Agreement.

 

The
Holder hereof may be treated by the Company, the warrant agent (if appointed), and all other persons dealing with this Warrant Certificate
as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented hereby, or to the transfer
hereof on the books of the Company, any notice to the contrary notwithstanding, and until such transfer on such books, the Company (and
the warrant agent, if appointed) may treat the Holder hereof as the owner for all purposes.

 

Neither
the Warrant nor this Warrant Certificate entitles any Holder to any of the rights of a stockholder of the Company.

 

    	2

    	 

    

 

[This
Warrant Certificate shall not be valid or obligatory for any purpose until it shall have been countersigned by the warrant agent.]*

 

	DATED:	 	 
	 	 	 
	 	 	AGEX THERAPEUTICS, INC.
	 	 	 
	(Seal)	 	By:	                        
	 	 	 
	 	 	Title:	 
	 	 	 
	Attest:                                                                         	 	 
	[COUNTERSIGNED: 	 	 
	WARRANT AGENT	 	 
	 	 	 
	By:                                                                              ]*	 	 
	Authorized Signature	 	 
	 	 	 
	                                                                    	 	 

 

	*	To
                                            be part of the Warrant only after the appointment of a warrant agent pursuant to the Warrant
                                            Agreement.

 

    	3

    	 

    

 

FORM
OF EXERCISE NOTICE

 

(To
be executed upon exercise of Warrant) To AgeX Therapeutics, Inc.:

 

The
undersigned hereby irrevocably elects to exercise the right of purchase represented by the within Warrant Certificate for, and to purchase
thereunder,                      shares of Common Stock, as provided for therein, and tenders herewith payment of the Warrant Price in full in
the form of a bank wire transfer to the account of the Company or by bank cashier’s check in the amount of

$                             .

 

The
undersigned hereby represents that (check any that apply):

 

☐
The undersigned is an “accredited investor” as defined in Rule 501 under the Securities Act.

 

☐
The undersigned is not a “U.S. person” as defined in Rule 902 under the Securities Act.

 

Please
issue a certificate or certificates for such shares of Common Stock in the name of, and pay any cash for any fractional share
to:

 

	 	 
	(Please Print Name)	 
	 	 
	 	 
	(Please Print Address)	 
	 	 
	 	 
	(Social Security Number or	 
	Other Taxpayer Identification Number)	 
	 	 
	 	 
	(Signature)	 

 

NOTE:
The above signature should correspond exactly with the name on the face of this Warrant Certificate or with the name of the assignee
appearing in the assignment form below.

 

And,
if said number of shares shall not be all the shares purchasable under the within Warrant Certificate, a new Warrant Certificate is to
be issued in the name of said undersigned for the balance remaining of the share purchasable thereunder, to the extent provided in the
Warrant Agreement, less any fraction of a share paid in cash.

 

    	4

    	 

    

 

ASSIGNMENT

 

(To
be executed only upon assignment of Warrant Certificate)

 

For
value received,                                       
hereby sells, assigns and transfers unto                                        
the within Warrant Certificate, together with all right, title and interest therein, and does hereby irrevocably constitute and
appoint                                      attorney, to transfer said Warrant Certificate on the books of the within-named Company, with full power of
substitution in the premises.

 

	 	Dated:		 

 

	 	 	 	 
	 	(Signature)	 	 	 
	 	 	 	 	 
	 	 	 	 	NOTE:	The above signature
    should correspond exactly with the name on the face of this Warrant Certificate.

 

    	5Exhibit
10.4

 

AMENDMENT
NO. 3

 

TO

 

REGISTRATION
RIGHTS AGREEMENT

 

This
Amendment No. 3, dated as of February 14, 2022 (the “Amendment”), is entered into by and between AgeX Therapeutics,
Inc., a California corporation (the “Company”) and Juvenescence, Limited, a company incorporated in the Isle of Man
(the “Holder”). Capitalized terms used in this Amendment and not otherwise defined herein shall have the meanings
ascribed thereto in the Registration Rights Agreement (as defined below).

 

WHEREAS,
the Company and Holder are parties to that certain Registration Rights Agreement dated as of August 13, 2019 (as amended by Amendment
No. 1 and Amendment No. 2 thereto, the “Registration Rights Agreement”);

 

WHEREAS,
the Company and Holder are entering into a Secured Convertible Promissory Note (the “Secured Note”) between the Company and
Holder providing the Company with a credit facility in the amount of up to $13,160,000 (the “Secured Note”), pursuant
to which the Company is obligated to issue to Holder common stock purchase warrants in accordance with the formula set forth in the Secured
Note in connection with each advance of funds under the Secured Note, which Warrants will be governed by a warrant agreement; and

 

WHEREAS,
in connection with the Secured Note, the Company and Holder have agreed to amend the Registration Rights Agreement as provided herein.

 

NOW
THEREFORE, in consideration of the terms and conditions set forth herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.
Amendments to Registration Rights Agreement.

 

1.1.
Section 1(e) through 1(i) of the Registration Rights Agreement is hereby deleted and replaced with the following Section 1(e)
through (j):

 

(e)
“Loan Agreement” means the Loan Facility Agreement between the Company and Holder, dated August 13, 2019, as amended,
and as may be further amended from time to time.

 

(f)
“Registrable Securities” means the Shares and Warrants. Any securities that are (i) distributed as a dividend or otherwise
with respect to Registrable Securities, (ii) issuable upon the exercise or conversion of Registrable Securities, or (iii) issued or issuable
in exchange for or through conversion of Registrable Securities pursuant to a recapitalization, stock-split, reorganization, merger,
consolidation or other transaction shall also constitute Registrable Securities.

 

(g)
“Second Loan Agreement” means the Secured Convertible Facility Agreement between the Company, as borrower thereunder,
Holder, as lender thereunder, and the subsidiaries of the Company named therein, as guarantors, as may amended from time to time.

 

(h)
“Shares” means, collectively, any and all shares of common stock, par value $0.0001 per share, of the Company issued
or to be issued by the Company pursuant to the terms of the Secured Note, the Loan Agreement or the Second Loan Agreement, including
any shares of common stock issuable by the Company pursuant to the exercise of Warrants or the conversion of any amounts outstanding
under the Secured Note, Loan Agreement or the Second Loan Agreement pursuant to the respective terms thereof.

 

(i)
“Warrants” means, collectively, any and all common stock purchase warrants issued or to be issued by the Company pursuant
to the terms of the Secured Note, the Loan Agreement or the Second Loan Agreement, including any shares of common stock issuable by the
Company pursuant to the exercise of Warrants or the conversion of any amounts outstanding under the Secured Note, the Loan Agreement
or the Second Loan Agreement, in each case as such number may be adjusted pursuant to the terms thereof.

 

    	 

     

    

 

(j)
“Secured Note” means the Secured Convertible Promissory Note between the Company and Holder dated February 14, 2022,
as may be amended from time to time.

 

1.2.
Each reference to the defined term “Warrant Shares” in the Registration Rights Agreement is hereby deleted:

 

2.
Effect. Except as specifically amended by this Amendment, the Registration Rights Agreement shall remain in full force and effect
and is hereby ratified and confirmed.

 

3.
Governing Law. This Amendment shall be governed in all respects by the laws of the State of California, as applied to contracts
entered into in California between California residents and to be performed entirely within California.

 

4.
Counterparts. This Amendment may be executed in any number of counterparts (including by separate counterpart signature pages),
each of which shall be an original, but all of which together shall constitute one instrument. Any counterpart of this Agreement may
be signed by electronic or facsimile, and such electronic or facsimile signature shall be deemed an original signature.

 

[signature
page follows]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

 

	COMPANY:
    	 
	 	 	 
	AGEX
    THERAPEUTICS, INC. 	 
	 	 	 
	By:	/s/
    Michael D. West	 
	 	 	 
	Name:
    	Michael
    D. West	 
	 	 	 
	Title	Chief
    Executive Officer	 
	 	 	 
	HOLDER:	 
	 	 	 
	JUVENESCENCE
    LIMITED 	 
	 	 	 
	By:	/s/
    Greg Bailey	 
	Name:	Greg
    Bailey	 
	Title:	Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00340-of-00352.parquet"}]]